Key points
- A comprehensive review published in Science challenges our interpretation of menopause and postmenopausal aging. Women spend about 40% of their lives after menopause, and the hormonal shift reshapes aging across nearly every organ. That makes the link between menopause and healthy aging central to women’s health.
- Research on menopause has lagged for decades. Menopause received just 0.2% of North American federal health research funding over 15 years. Misinterpretation of the WHI hormone trial affected menopause hormone treatment and research for decades.
- The details of menopause for each woman matter. For example, early menopause and severe hot flashes are linked to higher later-life risks of dementia, heart disease, and fractures.
- Hormone therapy isn’t a one-size-fits-all treatment, with more than 200 versions available. The dose, hormone type, route, and timing all change the balance of risks and benefits.
- The authors call for precision menopause care. Better data, longer and more inclusive studies, and dedicated funding are needed to tailor care to each woman.
Human health news
Tell me more about menopause and hormones.
Four decades after the final period
Picture a woman who reaches menopause at 51, the average age, and lives into her 80s. She will spend more than 30 years postmenopausal. Across the population, females spend about 40% of their lifespan after menopause, plus up to 10 years in the transition itself. These numbers anchor a new review in Science led by Dr. Liisa Galea of the Departments of Psychiatry and Pharmacology and Toxicology at the University of Toronto.
The argument is that menopause and healthy aging are tightly linked, because the transition is a turning point in how women age. Estrogen and progesterone receptors sit on every organ and most tissues. When these hormones fall, changes ripple through the brain, heart, immune system, bones, gut, skin, and metabolism. Menopause is also linked to faster “aging clocks” across several organs, regardless of a woman’s age in years.
The authors reject the idea that menopause is simply getting older. “Diminishing menopause to ‘just aging’ is a disservice to women,” they write. They call it a full-body hormonal change that affects each woman differently.
“Diminishing menopause to ‘just aging’ is a disservice to women.”
They also see an opportunity. A woman’s menopause type, timing, and symptoms offer early clues about her later risk of osteoporosis, heart disease, and dementia. That makes the transition a window for prevention. In the authors’ view, hormone therapy should not aim to reverse menopause, but to support healthy aging.
Why the science has lagged
If menopause matters this much, why do we know so little? Most medical research has historically been conducted on men, assuming the results would apply to everyone. Women’s health research has not caught up. The authors point to cultural silence around female aging, gendered taboos, and a shortage of dedicated research. Together, these let dogma stand in for evidence.
Research funding tells the story. Over 15 years, only 0.2% of federal health research investment in North America went to menopause questions. That is about one dollar in every 500.
The gaps reach the clinic, too. Most medical schools have no dedicated menopause curriculum. Effective treatments exist, yet fewer than 15% of women with symptoms receive them. About 10% of women leave the workforce because of menopause symptoms. Many feel dismissed by clinicians and turn to supplements and unregulated hormone products instead.
Clinical trials have limits as well. Trials of hormone therapy for chronic conditions lasted about 4.3 years on average, while women in real life use it for an average of 5.4 years and sometimes nearly 15. Trials have also tended to exclude women with hot flashes, partly because “blinding” the trials is hard. Yet those women may benefit most.
The long shadow of the WHI
One trial shaped two decades of care. The Women’s Health Initiative (WHI) was the largest randomized trial of hormone therapy. It found that one combination raised the risk of heart disease, breast cancer, and dementia compared with a placebo, and the investigators stopped it early. That combination paired oral conjugated equine estrogens, a horse-derived estrogen mix, with a synthetic progestin called medroxyprogesterone acetate (MPA). The estrogen alone did not show those risks.
The WHI asked whether hormone therapy promoted health in older women, 10 or more years past menopause. Critics have since questioned its design, including when treatment started and which hormones were used. Yet the medical community applied its findings to every hormone therapy. The result was that hormone prescriptions fell by more than 60%, and blackbox warnings went on all products. In 2020, less than 5% of menopausal women in the U.S. used hormone therapy.
In 2025, the U.S. Food and Drug Administration announced it would remove the boxed warning. The International Menopause Society objected in part, supporting removal only for vaginal estrogens.
Summarizing the review: nine themes
The authors of the review provided a comprehensive assessment of the menopause transition, postmenopausal aging, and the many factors that affect how any one person responds. This is a brief summary of topics covered:
- Menopause is a whole-body transition. As estradiol and progesterone fall around menopause, both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) rise to stimulate the ovaries to produce more sex hormones. This affects hormone receptors found throughout the body. Blood vessels lose elasticity and metabolism slows, while blood pressure, LDL cholesterol, and belly fat climb. Many of these changes persist well into the postmenopausal years.
- Symptoms go far beyond hot flashes. Hot flashes and night sweats affect 80% of women, but at least 72 menopause symptoms have been reported. The most common symptoms involve the brain, with brain fog and mood changes affecting up to 80% of women. The menopause transition increases the risk of bipolar disorder and depression. Symptoms last 7.4 years on average, yet about a third of women aged 65 to 79 still have hot flashes or night sweats.
- How menopause happens matters. In North America, about 74% of menopause is spontaneous, 10% surgical, and 2% chemical, caused by treatments such as chemotherapy. Another 10% comes early (before age 45) or prematurely (before age 40). Even a hysterectomy that leaves the ovaries in place brings menopause about four years earlier and raises early-onset dementia risk. And the postmenopausal ovary isn’t dormant; it still produces hormones and inflammatory signals.
- When menopause happens matters. Early or premature menopause is reliably linked to higher risks of death, dementia, heart disease, fractures, and several other conditions. It is also tied to faster biological aging on DNA- and protein-based clocks. No one yet knows whether early menopause causes faster aging, or whether both stem from a shared cause.
- Symptoms can be warning signs. Severe hot flashes, especially at night, are linked to poorer memory and thinking, and to brain changes tied to Alzheimer’s disease. Severe, frequent symptoms are also linked to mild cognitive impairment, an early stage before dementia. Women with severe hot flashes are up to three times as likely to have depressive symptoms.
- Experiences differ by ethnicity and culture. Black and South Asian women in North America tend to reach menopause earlier. Black American women report more frequent and severe hot flashes but receive fewer hormone prescriptions. Culture also shapes how openly women discuss symptoms.
- Hormone therapy is not one treatment. More than 200 versions exist, differing in dose, type of estrogen and progestogen, route, timing, and schedule. The estradiol patch alone allows at least 70 combinations. Each has its own balance of risks and benefits.
- The details of a formulation matter. Oral estrogen pills, like the equine-derived estrone used in the WHI study, have higher risks. Estrogen absorbed through the skin skips the liver and carries a two- to four-fold lower blood clot risk than pills. The authors tie MPA to most of the WHI’s poorer outcomes. Transdermal estradiol and micronized progesterone, which protect the uterus, have much lower risk profiles and have shown better results for memory and thinking. Overall, hormone therapy remains the most effective treatment for hot flashes and cuts fractures by 20 to 40%.
- Timing, duration, and personal history matter. Starting therapy closer to menopause may lower heart disease risk. Continuing therapy later in life may have health benefits beyond symptom control, such as preserving bone health. A woman’s contraceptive use, pregnancies, premenstrual symptoms, hormone sensitivity, and genes may shape how she responds to menopause, though this research is early.
Where menopause research and care need to go next
The authors call for precision menopause care, tailored to each woman’s symptoms, genetics, and hormone history, to support healthy aging after menopause. Precision medicine has already transformed breast cancer care. Menopause, they argue, is the next frontier in women’s health. They make several specific recommendations:
- Treat menopause as a life stage that needs follow-up care. The authors urge clinicians to provide ongoing care, much as they do for pregnancy and the postpartum period. They also want fixed time limits on hormone therapy reconsidered, since up to 45% of women over 65 still have hot flashes.
- Rethink how symptoms are studied. The authors pose two pointed questions to researchers. Are there really only 11 key symptoms? Do symptoms really stop after five years? Their assessment is that these assumptions are incorrect.
- Collect better data. Studies should record women’s full hormone histories, including contraceptives, past hormone therapy, and the exact products used. This will help to clarify results of research. Ethnicity, location, and social context also belong in the data.
- Test the full range of treatments. Trials since the WHI have not evaluated options such as low-dose vaginal estrogens and transdermal gels and sprays in younger women with symptoms or in racially diverse groups. Observational and long-term cohort studies, analyzed with new statistical tools, can help fill gaps that clinical trials leave.
- Study hormone sensitivity and genetics. Some women react strongly to rising hormones and others to falling ones. Early work suggests that genes, including the Alzheimer’s risk gene APOE4, may change how hormone therapy affects the brain.
- Communicate precisely and fund boldly. “Estrogen” and “hormone therapy” are not single things, and papers and headlines should make that clear. The authors also urge foundations and governments to fund paradigm-shifting menopause research.
The take-home message
For women considering hormone therapy for menopause symptoms, the practical message is to ask detailed questions: which estrogen, which progestogen, which route, and why. Make those choices with an experienced clinician who knows your history.
The bigger message is for science and medicine. Menopause spans more than a third of the lifespan for half the world’s population, so it is no niche topic. How we study and treat menopause will shape healthy aging for millions of women.
Find more details on hormones for menopause and articles on menopause.
